Targacept Presents Data at the 35th Annual Meeting of the Society for Neuroscience
Posters Highlight Research on the Alpha7 Receptor Subtype
Winston-Salem, NC
November 15, 2005
Targacept, Inc., a clinical-stage central nervous system-focused biopharmaceutical company, announced today that it presented research findings at the 35th annual meeting of the Society for Neuroscience.
Targacept’s compounds are designed to act on a class of therapeutic targets called neuronal nicotinic acetylcholine receptors (NNRs) that are involved in regulating functions such as attention, memory and mood. Targacept researchers presented five posters summarizing recent preclinical work on compounds targeting either the a7 NNR or both the a7 and a4b2 NNRs. The a7 and a4b2 NNRs have been implicated in a number of CNS disorders. One of the Targacept posters described the results of several animal studies suggesting that a Targacept compound selective for the α7 NNR enhances cognition and reduces sensory gating deficits. Other posters described the results of studies on the development of novel mutant targets as tools in preclinical screening and the profile of several late preclinical compounds.
About Targacept Targacept is a clinical-stage biopharmaceutical company engaged in the design, discovery and development of drugs to treat multiple diseases and disorders of the central nervous system by selectively targeting a class of receptors known as neuronal nicotinic acetylcholine receptors, or NNRs. Targacept is located in Winston-Salem, North Carolina.
Contacts:
Alan Musso, VP and CFO
Targacept, Inc.
Tel: (336) 480-2186
Email: alan.musso@targacept.com
Michelle Linn
Linnden Communications
Tel: (508) 869-0138
Email: michlinn@charter.net
Back to Newsroom